Zentera Therapeutics has been spun off by oncology therapy developer Zentalis Pharmaceuticals with a series A round led by Tybourne Capital Management.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Led by UCLA’s Sri Kosuri, Octant is working on drugs for complex diseases and will use the series A funding to further develop its platform.

Takeda and existing investor Allianz X took part in a series C round closed in the wake of heightened demand for Amwell's telehealth technology platform.

Asahi Kasei Medical contributed to a round that took the total raised by the microbial detection technology provider past $255m.

Pfizer, Lundbeckfonden Ventures and Biomed Ventures have all taken part in a round for the anti-infective therapy developer that has now passed $90m.

The corporate-backed health management service raised the cash from Perceptive Advisors and has used $30m to buy musculoskeletal-focused Physera.

Vetmeduni has joined forces with incubator Accent to boost resources for commercialising its veterinary research.

GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.